Tuesday, 27 October 2026European Markets

Energy Stocks Surge 29% In 5 Sessions: Is It Time To Invest?

Loading stream...

(VIANEWS) - NEW SOURCES ENERGY (AEX-Index: NSE.AS) experienced an extraordinary surge, climbing 29.03% from EUR0.03 to EUR0.04 at 15:16 EST on Wednesday - representing two consecutive sessions of gains and a 0.45% jump on its index price to EUR738.25 after three consecutive down periods - after experiencing 38.46% decline from its 52-week high of EUR0.07. NEW SOURCES ENERGY had last closed with EUR0.04, representing 38.46% decline since its 52 week high of EUR0.07 on October 27 th.

About NEW SOURCES ENERGY

New Sources Energy N.V. specializes in the design, development, exploitation and investment of renewable energy projects for electricity generation. Formerly known as Management Share NV, they were rebranded in July 2011 to become New Sources Energy N.V. with headquarters located in Amersfoort in Netherlands.

Yearly Analysis

At its current stock price of EUR0.04, NEW SOURCES ENERGY is trading significantly lower than its 52-week high of EUR0.07 but higher than its 52-week low of EUR0.01, suggesting it has experienced significant price fluctuation over the past year, potentially prompting investors to view it as undervalued or oversold at this level. However, investors should remember that past performance does not guarantee future outcomes and conduct further analysis and research before making investment decisions.

Technical Analysis

NEW SOURCES ENERGY has experienced an accelerated downward trend, falling well below both its 50-day and 200-day moving averages, which may indicate bearish market conditions. Although its last reported volume has significantly declined from its usual trading activity of 77,278, at only 125 the stock is still indicative of relatively limited trading activity. The stock's volatility has fluctuated, with average intraday variation averages of 8.96% for last week, month, and quarter all being 8.96% respectively; its highest amplitude of average volatility being 14.68% during month 1 and 12.99% during quarter 3. According to the stochastic oscillator, which measures overbought and oversold conditions, NEW SOURCES ENERGY's stock may be considered oversold (=20). This may present investors with an opportunity to purchase it at lower prices in anticipation of potential growth in value in the near future. Overall, NEW SOURCES ENERGY's current market conditions indicate a bearish trend with low trading activity and potential oversold conditions. Investors should carefully consider these aspects prior to making any decisions regarding investment decisions in this stock.

Equity Analysis

ROE of negative 288.52% indicates that a company has suffered losses and failed to generate profits for shareholders, prompting concerns among investors that this could indicate financial issues or inadequate management of its resources. Note that negative return on equity does not indicate a company is facing dire financial conditions and cannot recover, but investors should approach it with caution and carefully consider other metrics and the overall health of the business before making investment decisions. Conclusion: With an ROE of -288.52%, this stock does not represent an attractive investment opportunity as it does not generate profits for shareholders. Therefore, investors are advised to conduct additional research into its financial performance and overall business strategy before making their final investment decisions.

More news about NEW SOURCES ENERGY (NSE.AS).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biotech Catalyst Window: ESMO Data, the Ivonescimab PDUFA and Small-Cap Delistings
Mid-October to November 2026 is a dense catalyst period for clinical-stage biotech. Positive late-stage readouts (ALOFT-IPF, TELIGAN, MIUDELLA, the duvakitug extension) and the ESMO 2026 presentations lead up to the FDA's 14 November PDUFA date for the ivonescimab BLA. At the opposite end of the market, Spago Nanomedical is moving to delist from Nasdaq First North, which shows how hard it is for micro-cap developers to fund themselves. Value is concentrating in companies with late-stage data and near-term regulatory outcomes.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,994
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,994 facts checked against source5,500 source documents archived
Query this data → isubstrate.com